DEMECAN announces the signing of a three-year supply agreement with Australian-based medical cannabis producer, Little Green Pharma, marking yet another milestone in DEMECAN’s path to guarantee a consistent supply of pharmaceutical grade cannabis to patients in Germany. The agreement is for an annual amount of at least 1,000 kg of dried flower or 48,000 units of medical cannabis oil.
"We are delighted to work together with Little Green Pharma to ensure the supply of high-quality medical cannabis products for German patients," says Dr. Cornelius Maurer, managing director at DEMECAN.
The first shipments of medical cannabis from Australia are expected in the second half of 2020 and will complement the supply from the Netherlands, Canada, and other countries as well as DEMECAN’s own domestic production.
Berlin, February 27, 2020
About DEMECAN:
DEMECAN is the only German company that covers the entire value chain for medical cannabis from cultivation, processing, and storage to distribution to pharmacies. In May 2019, the Federal Institute for Drugs and Medical Devices (BfArM) awarded DEMECAN the contract to grow medical cannabis. DEMECAN is based in Berlin.The cultivation and processing of medical cannabis takes place in a second facility near Dresden.
Exchange and dialogue:
We are always open for questions about DEMECAN, medical cannabis, and opportunities around phytopharmacological research. Any questions related to regulatory affairs and all questions by regulatory authorities should be directed to info@demecan.de.
DEMECAN is pleased to announce receipt of AmRadV approval from the German cannabis agency, marking the start of cannabis flower sales from the Netherlands. The flowers, manufactured by Bedrocan, are sold exclusively for medical purposes through pharmacies.
The AmRadV regulates the sale of medicinal products treated with ionizing radiation to protect patients from bacteria, mold, or viruses. By late last year, cannabasis supply bottlenecks in Germanyresulted from a lack of AmRadV approvals ofimporters. DEMECAN will now fill this supply gapand ensure that patients have access to medical cannabis.
"DEMECAN was selected by the German government to ensure the production and supply of medical cannabis and we believe the import of medical cannabis from our neighbours is a logical first step, as it guarantees supply for patients in Germany," says Dr. Adrian Fischer, physician and managing director at DEMECAN. "The ability for patients to obtain these pharmaceuticals through DEMECAN is a welcome development in the interest of German patients.”The build-out for DEMECAN’s medical cannabis production facility, in parallel to its import and sales business, is progressing as well. Last year, the company was one of three commissioned by the federal government to grow and process medical cannabis of highest pharmaceutical quality. This guarantees access to cannabis for patients in Germany. The first harvest will be ready by the end of the year.
Dresden, February 24, 2020
About DEMECAN:
DEMECAN is the only German company that covers the entire value chain for medical cannabis from cultivation, processing, and storage to distribution to pharmacies. In May 2019, the Federal Institute for Drugs and Medical Devices (BfArM) awarded DEMECAN the contract to grow medical cannabis. DEMECAN is based in Berlin.The cultivation and processing of medical cannabis takes place in a second facility near Dresden.
Exchange and dialogue:
We are always open for questions about DEMECAN, medical cannabis, and opportunities aroundphytopharmacological research. Any questions related to regulatory affairs and all questions by regulatory authorities should be directed to info@demecan.de.
